Zobrazeno 1 - 10
of 38
pro vyhledávání: ''
Autor:
Xavier Dolcet, Sonia Gatius, Nuria Eritja, Cristina Mirantes, Maria Santacana, Isidre Felip, Maria Alba Dosil, Xavier Matias-Guiu
Publikováno v:
European journal of cancer (Oxford, England : 1990). 63
The phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) axis is frequently dysregulated in cancer due to mutations in different nodes of the pathway or constitutive activation of receptor tyrosine kinases. Mul
Publikováno v:
European journal of cancer (Oxford, England : 1990). 49(8)
Aim Recently, sildenafil was reported to be an inhibitor of P-glycoprotein (P-gp/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) in vitro. We have now investigated the in vivo potency of sildenafil. Methods By using wild-type and Abcb1;Abcg2
Publikováno v:
European journal of cancer (Oxford, England : 1990). 46(11)
The combination of irinotecan and erlotinib has been evaluated in clinical trials, although toxicity has been significant. We aimed to investigate the effect of erlotinib on SN-38 glucuronidation, and the association between UGT1A polymorphisms and S
Publikováno v:
European journal of cancer (Oxford, England : 1990). 45(11)
Introduction XK469 is a novel topoisomerase II inhibitor structurally akin to several propionic acid derivatives, such as ibuprofen and diclofenac, which are metabolised by CYP2C9. We report eight subjects who experienced significant elevation of INR
Autor:
Richard Eastell, Anna Miyamoto, Richard D. Finkelman, Glen Clack, Eugene V. McCloskey, Geza Lakner, Rosemary A. Hannon, William D. Fraser
Publikováno v:
European journal of cancer (Oxford, England : 1990). 43(17)
Given potential differences between the skeletal and other effects of the third generation aromatase inhibitors (AIs), we conducted an open, randomised Phase I study, comparing the effects of three licensed AIs on bone turnover markers, lipid profile
Autor:
Marc Salzberg, Christoph Rochlitz, R. Morant, Daniel Rauch, Markus Borner, Jean-Alexandre Bauer
Publikováno v:
European journal of cancer (Oxford, England : 1990). 42(15)
2006 Elsevier Ltd. All rights reserved. Metastatic urothelial cancer is a rapidly fatal disease with a patients suffering from advanced TCC. More recently,the median survival of less than one year. Despite treatment with radical cystectomy in patient
Autor:
Mathias Locher, Cornelia Quadt, Ralf Oberneder, Dorothea Weckermann, Petra Kirchinger, Tobias Raum, Beatrice Ebner, Nadja Prang, Eugen Leo, Patrick A. Baeuerle
Publikováno v:
European journal of cancer (Oxford, England : 1990). 42(15)
Aim of the study Adecatumumab (also known as MT201) is a human recombinant IgG1 monoclonal antibody binding with low affinity to epithelial cell adhesion molecule (EpCAM). To explore safety, pharmacokinetics and pharmacodynamics of adecatumumab, a ph
Autor:
Eugene V. McCloskey
Publikováno v:
European journal of cancer (Oxford, England : 1990). 42(8)
Low oestradiol levels in women are associated with decreased bone mineral density (BMD) and increased fracture risk. The third-generation aromatase inhibitors (AIs; anastrozole, letrozole, and exemestane) are used in the treatment of early and advanc
Autor:
Marie-Christine Etienne-Grimaldi, Gérard Milano, Patricia Formento, Jean-Louis Fischel, Nicolas Magné, Jean-Michel Hannoun-Levi
Publikováno v:
European journal of cancer (Oxford, England : 1990). 40(18)
Epidermal growth factor receptor (EGFR) and HER-2 are associated with a poor prognosis in various cancers, including prostate cancer. Inhibition of these receptors may provide a treatment for hormone-refractory prostate cancer. The presence of HER-2
Publikováno v:
European journal of cancer (Oxford, England : 1990). 40(15)
The inhibition of glyoxalase I leads to antitumour activity through the accumulation of methylglyoxal. Our earlier observations suggested that methotrexate (MTX) may affect the glyoxalase system. This prompted a serial study of the drug on this metab